Table of Contents	
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549	
FORM 10-Q	
(Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 1934	N 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
For the quarterly period ended January 2, 2016	
OR	
" TRANSITION REPORT PURSUANT TO SECTION 1934	N 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
For the transition period from to	
Commission File Number: 1-05129	
INC. (Exact name of registrant as specified in its charter)	
New York State (State or other jurisdiction of incorporation or organization) East Aurora, New York (Address of principal executive offices) (716) 652-2000 (Telephone number including area code)	16-0757636 (I.R.S. Employer Identification No.) 14052-0018 (Zip Code)

Former name, former address and former fiscal year, if changed since last report.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No "

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ý No "

MOOG INC. Form 10-O

February 01, 2016

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ý Accelerated filer " Non-accelerated filer " Smaller reporting company "

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes " No  $\acute{y}$ 

The number of shares outstanding of each class of common stock as of January 26, 2016 was:

Class A common stock, \$1.00 par value, 33,364,542 shares

Class B common stock, \$1.00 par value, 3,363,623 shares

# Moog Inc. QUARTERLY REPORT ON FORM 10-Q TABLE OF CONTENTS

PART I	FINANCIAL INFORMATION			
	Item 1	Financial Statements:		
		Consolidated Condensed Balance Sheets as of January 2, 2016 and October 3, 2015	<u>3</u>	
		Consolidated Condensed Statements of Earnings for the Three Months Ended January 2, 2016 and January 3, 2015	<u>4</u>	
		Consolidated Condensed Statements of Comprehensive Income (Loss) for the Three Months Ended January 2, 2016 and January 3, 2015	<u>5</u>	
		Consolidated Condensed Statements of Cash Flows for the Three Months Ended January 2, 2016 and January 3, 2015	<u>6</u>	
		Notes to Consolidated Condensed Financial Statements	7	
	Item 2	Management's Discussion and Analysis of Financial Condition and Results of Operations	<u>21</u>	
	Item 3	Quantitative and Qualitative Disclosures about Market Risk	<u>37</u>	
	Item 4	Controls and Procedures	<u>37</u>	
PART II	OTHER IN	FORMATION		
	Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	<u>38</u>	
	Item 6	<u>Exhibits</u>	<u>39</u>	
SIGNAT	<u>URES</u>		<u>40</u>	
2				

PART I FINANCIAL INFORMATION Item 1. Financial Statements Moog Inc. Consolidated Condensed Balance Sheets (Unaudited)		
(dollars in thousands)	January 2, 2016	October 3, 2015
ASSETS Current assets Cash and cash equivalents Receivables Inventories Deferred income taxes Prepaid expenses and other current assets	\$323,318 690,876 501,653 91,225 37,933	\$309,853 698,419 493,360 91,210 34,653
Total current assets	1,645,005	1,627,495
Property, plant and equipment, net of accumulated depreciation of \$680,860 and \$677,168, respectively	535,393	536,756
Goodwill Intangible assets, net Other assets Total assets LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities	752,791 143,048 40,603 \$3,116,840	737,212 143,723 41,285 \$3,086,471
Short-term borrowings	\$1,363	\$83
Current installments of long-term debt	443	34
Accounts payable	147,971	165,973
Accrued salaries, wages and commissions	115,457	125,270
Customer advances	166,491	167,423
Contract loss reserves	29,724	30,422
Other accrued liabilities	106,740	116,300
Total current liabilities	568,189	605,505
Long-term debt, excluding current installments	1,130,569	1,075,067
Long-term pension and retirement obligations	333,441	348,239
Deferred income taxes	69,136	60,209
Other long-term liabilities	3,363	2,919
Total liabilities	2,104,698	2,091,939
Commitments and contingencies (Note 17)	— 0.106	
Redeemable noncontrolling interest	9,106	
Shareholders' equity Common stock	51,280	51,280
Other shareholders' equity	951,756	943,252
Total shareholders' equity	1,003,036	994,532
Total liabilities and shareholders' equity	\$3,116,840	\$3,086,471
See accompanying Notes to Consolidated Condensed Financial Statements.	Ψ2,110,010	Ψ2,000,171
1 7 5		

# Table of Contents

Moog	Inc.
------	------

Consolidated Condensed Statements of Earnings (Unaudited)

(Chadaned)	Three Months Ended			
(dollars in thousands, except per share data)	January 2, 2016	January 3, 2015		
Net sales	\$568,457	\$630,523		
Cost of sales	406,997	446,605		
Gross profit	161,460	183,918		
Research and development	34,798	31,321		
Selling, general and administrative	82,994	97,827		
Interest	8,322	5,368		
Restructuring	273			
Other	(582	) (36	)	
Earnings before income taxes	35,655	49,438	,	
Income taxes	9,495	14,173		
Net earnings attributable to common shareholders and noncontrolling interest	\$26,160	\$35,265		
Net earnings (loss) attributable to noncontrolling interest	(81	) —		
Net earnings attributable to common shareholders	\$26,241	\$35,265		
Net earnings per share attributable to common shareholders				
Basic	\$0.71	\$0.87		
Diluted	\$0.71	\$0.86		
Average common shares outstanding				
Basic	36,713,949	40,594,886		
Diluted	37,028,331	41,080,179		
See accompanying Notes to Consolidated Condensed Financial Statements.		, ,		

# Table of Contents

Moog Inc.

Consolidated Condensed Statements of Comprehensive Income (Loss) (Unaudited)

(	Three Montl	hs Ended
(dollars in thousands)	January 2, 2016	January 3, 2015
Net earnings attributable to common shareholders and noncontrolling interest	\$26,160	\$35,265
Other comprehensive income (loss), net of tax:		
Foreign currency translation adjustment	(23,199	) (42,906 )
Retirement liability adjustment	5,332	5,574
Change in accumulated loss on derivatives	438	250
Other comprehensive income (loss), net of tax	(17,429	) (37,082
Comprehensive income (loss)	\$8,731	\$(1,817)
Comprehensive income (loss) attributable to noncontrolling interest	(81	) —
Comprehensive income (loss) attributable to common shareholders	\$8,812	\$(1,817)
See accompanying Notes to Consolidated Condensed Financial Statements.		

Moog Inc.

Consolidated Condensed Statements of Cash Flows (Unaudited)

	Three Month	s Ended	
(dollars in thousands)	January 2,	January 3,	
(dollars in diousalids)	2016	2015	
CASH FLOWS FROM OPERATING ACTIVITIES			
Net earnings attributable to common shareholders and noncontrolling interest	\$26,160	\$35,265	
Adjustments to reconcile net earnings to net cash provided (used) by operating			
activities:			
Depreciation	19,208	19,833	
Amortization	5,877	6,741	
Deferred income taxes	3,532	6,713	
Equity-based compensation expense	936	3,398	
Other	804	1,111	
Changes in assets and liabilities providing (using) cash:			
Receivables	5,221	62,772	
Inventories	(11,131		)
Accounts payable	(22,522		)
Customer advances	(498		)
Accrued expenses	(17,114	) (35,922	)
Accrued income taxes	(2,685	) (3,060	)
Net pension and post retirement liabilities	(5,709	) 970	
Other assets and liabilities	(2,534	) 3,580	
Net cash provided (used) by operating activities	(455	) 78,473	
CASH FLOWS FROM INVESTING ACTIVITIES			
Acquisitions of businesses, net of cash acquired	(11,016	) —	
Purchase of property, plant and equipment	(12,305	) (20,160	)
Other investing transactions	1,021	71	
Net cash used by investing activities	(22,300	) (20,089	)
CASH FLOWS FROM FINANCING ACTIVITIES			
Net short-term repayments	_	(3,236	)
Proceeds from revolving lines of credit	148,605	123,170	
Payments on revolving lines of credit	(93,605	) (337,170	)
Payments on long-term debt	(9,540		)
Proceeds from senior notes, net of issuance costs	_	294,718	
Proceeds from sale of treasury stock	2,230	9,951	
Purchase of outstanding shares for treasury	(3,034	) (122,443	)
Purchase of stock held by SECT	(1,020	) (4,460	)
Excess tax benefits from equity-based payment arrangements	580	4,855	
Net cash provided (used) by financing activities	44,216	(39,849	)
Effect of exchange rate changes on cash	(7,996	) (9,587	)
Increase in cash and cash equivalents	13,465	8,948	
Cash and cash equivalents at beginning of period	309,853	231,292	
Cash and cash equivalents at end of period	\$323,318	\$240,240	
See accompanying Notes to Consolidated Condensed Financial Statements.			

### **Table of Contents**

Moog Inc.

Notes to Consolidated Condensed Financial Statements

Three Months Ended January 2, 2016

(Unaudited)

(dollars in thousands, except per share data)

Note 1 - Basis of Presentation

The accompanying unaudited consolidated condensed financial statements have been prepared by management in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, all adjustments consisting of normal recurring adjustments considered necessary for the fair presentation of results for the interim period have been included. The results of operations for the three months ended January 2, 2016 are not necessarily indicative of the results expected for the full year. The accompanying unaudited consolidated condensed financial statements should be read in conjunction with the financial statements and notes thereto included in our Form 10-K for the fiscal year ended October 3, 2015. All references to years in these financial statements are to fiscal years.

**Recent Accounting Pronouncements** 

In April 2014, the FASB issued ASU No. 2014-08, "Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity." This ASU is intended to change the criteria for reporting discontinued operations and enhance convergence of the FASB's and the International Accounting Standard Board's (IASB) reporting requirements for discontinued operations. The provisions of this ASU are effective for fiscal years beginning after December 15, 2014 and interim periods within those fiscal years. We adopted this amendment in the first quarter of 2016. The adoption of this standard did not have a material impact on our financial statements.

Note 2 - Acquisition and Divestiture

In 2016, we acquired a 70% ownership in Linear Mold and Engineering, a Livonia, Michigan-based company providing engineering, manufacturing and production consulting services to customers across a wide range of industries, including aerospace, defense, energy and industrial. The purchase price, net of acquired cash, was \$25,751 consisting of \$11,016 in cash, issuance of a \$1,280 unsecured note, assumption of \$10,455 of debt and contingent consideration with an initial fair value of \$3,000. The acquisition also includes a redeemable noncontrolling interest in the remaining 30%, which is exercisable beginning three years from the date of acquisition. This acquisition is included in of our Aircraft Controls segment. The purchase price allocation is subject to adjustments as we obtain additional information for our estimates during the measurement period.

In 2015, we sold the Rochester, New York and Erie, Pennsylvania life sciences operations of our Medical Devices segment for \$2,988 in cash.

### **Table of Contents**

# Note 3 - Receivables

Receivables consist of:

	January 2,	October 3,	
	2016	2015	
Accounts receivable	\$297,578	\$291,188	
Long-term contract receivables:			
Amounts billed	98,872	113,565	
Unbilled recoverable costs and accrued profits	284,048	286,395	
Total long-term contract receivables	382,920	399,960	
Other	15,626	12,557	
Total receivables	696,124	703,705	
Less allowance for doubtful accounts	(5,248	) (5,286	)
Receivables	\$690,876	\$698,419	

We securitize certain trade receivables in transactions that are accounted for as secured borrowings (Securitization Program). We maintain a subordinated interest in a portion of the pool of trade receivables that are securitized. The retained interest, which is included in Receivables in the consolidated condensed balance sheets, is recorded at fair value, which approximates the total amount of the designated pool of accounts receivable. Refer to Note 6, Indebtedness, for additional disclosures related to the Securitization Program.

### Note 4 - Inventories

Inventories, net of reserves, consist of:

	January 2,	October 3,
	2016	2015
Raw materials and purchased parts	\$192,094	\$188,843
Work in progress	242,663	243,373
Finished goods	66,896	61,144
Inventories	\$501,653	\$493,360

There are no material inventoried costs relating to long-term contracts where revenue is accounted for using the percentage of completion, cost-to-cost method of accounting as of January 2, 2016 or October 3, 2015.

Note 5 - Goodwill and Intangible Assets

The changes in the carrying amount of goodwill are as follows:

	Aircraft Controls	Space and Defense Controls	Industrial Systems	Components	Medical Devices	Total	
Balance at October 3, 2015	\$188,525	\$158,213	\$110,843	\$217,763	\$61,868	\$737,212	
Acquisitions	21,306		_			21,306	
Foreign currency translation	(1,713	)(334	)(3,841	)466	(305	) (5,727	)
Balance at January 2, 2016	\$208,118	\$157,879	\$107,002	\$218,229	\$61,563	\$752,791	

Goodwill at January 2, 2016, in our Medical Devices reporting unit, is net of a \$38,200 accumulated impairment loss. Certain factors, including industry conditions and the future profitability of our business, might have a negative impact on the carrying value of our goodwill and we may incur additional goodwill impairment charges.

The components of intangible assets are as follows:

		January 2, 2016			October 3, 2015		
	Weighted- Average Life (years)	Gross Carrying Amount	Accumulated Amortization		Gross Carrying Amount	Accumulated Amortization	
Customer-related	11	\$175,569	\$(112,210	)	\$171,779	\$(110,697	)
Program-related	18	74,004	(27,962	)	75,720	(27,463	)
Technology-related	9	72,789	(50,468	)	73,299	(49,723	)
Marketing-related	9	27,079	(17,101	)	25,997	(16,648	)
Other	9	4,623	(3,275	)	4,772	(3,313	)
Intangible assets	12	\$354,064	\$(211,016	)	\$351,567	\$(207,844	)

Substantially all acquired intangible assets other than goodwill are being amortized. Customer-related intangible assets primarily consist of customer relationships. Program-related intangible assets consist of long-term programs represented by current contracts and probable follow on work. Technology-related intangible assets primarily consist of technology, patents, intellectual property and software. Marketing-related intangible assets primarily consist of trademarks, trade names and non-compete agreements.

Amortization of acquired intangible assets was \$5,811 for the three months ended January 2, 2016 and \$6,660 for the three months ended January 3, 2015. Based on acquired intangible assets recorded at January 2, 2016, amortization is expected to be approximately \$22,800 in 2016, \$19,400 in 2017, \$18,000 in 2018, \$16,700 in 2019 and \$15,300 in 2020.

Note 6 - Indebtedness

Short-term borrowings consist of:

	January 2,	October 3,	
	2016	2015	
Lines of credit	\$83	\$83	
Other short-term debt	1,280	_	
Short-term borrowings	\$1,363	\$83	

We maintain short-term line of credit facilities with banks throughout the world that are principally demand lines subject to revision by the banks.

Long-term debt consists of:

	January 2,	October 5,
	2016	2015
U.S. revolving credit facility	\$730,000	\$675,000
Senior notes	300,000	300,000
Securitization program	100,000	100,000
Obligations under capital leases	1,012	101
Senior debt	1,131,012	1,075,101
Less current installments	(443	) (34
Long-term debt	\$1,130,569	\$1,075,067

Ianuary 2

October 3

Our U.S. revolving credit facility has a capacity of \$1,100,000 and matures on May 22, 2019. It also provides an expansion option, which permits us to request an increase of up to \$200,000 to the credit facility upon satisfaction of certain conditions. The credit facility is secured by substantially all of our U.S. assets.

On November 21, 2014, we completed the sale of \$300,000 aggregate principal amount of 5.25% senior notes due December 1, 2022 at par with interest paid semiannually on June 1 and December 1 of each year. The aggregate net proceeds of \$294,430 were used to repay indebtedness under our U.S. bank credit facility, thereby increasing the unused portion of our revolving credit facility.

The Securitization Program was extended on February 10, 2015 and matures on February 10, 2017 and effectively increases our borrowing capacity by up to \$100,000. Under the Securitization Program, we sell certain trade receivables and related rights to an affiliate, which in turn sells an undivided variable percentage ownership interest in the trade receivables to a financial institution, while maintaining a subordinated interest in a portion of the pool of trade receivables. Interest for the Securitization Program is based on 30-day LIBOR plus an applicable margin. A commitment fee is also charged based on a percentage of the unused amounts available and is not material. The agreement governing the Securitization Program contains restrictions and covenants which include limitations on the making of certain restricted payments, creation of certain liens, and certain corporate acts such as mergers, consolidations and sale of substantially all assets. The Securitization Program has a minimum borrowing requirement equal to the lesser of either 80% of our borrowing capacity or 100% of our borrowing base, which is a subset of the trade receivables sold under this agreement. As of January 2, 2016, our minimum borrowing requirement is \$80,000.

### Note 7 - Product Warranties

In the ordinary course of business, we warrant our products against defects in design, materials and workmanship typically over periods ranging from twelve to sixty months. We determine warranty reserves needed by product line based on historical experience and current facts and circumstances. Activity in the warranty accrual is summarized as follows:

Three Months Ended

	111100 1/1011111	,	
	January 2,	January 3,	
	2016	2015	
Warranty accrual at beginning of period	\$18,660	\$19,953	
Warranties issued during current year	2,418	1,465	
Adjustments to pre-existing warranties	(134	) (1,132	)
Reductions for settling warranties	(1,253	) (1,238	)
Foreign currency translation	(300	) (722	)
Warranty accrual at end of period	\$19,391	\$18,326	

Note 8 - Derivative Financial Instruments

We principally use derivative financial instruments to manage interest rate risk associated with long-term debt and foreign exchange risk related to foreign operations and foreign currency transactions. We enter into derivative financial instruments with a number of major financial institutions to minimize counterparty credit risk. Derivatives designated as hedging instruments

Interest rate swaps are used to adjust the proportion of total debt that is subject to variable and fixed interest rates. The interest rate swaps are designated as hedges of the amount of future cash flows related to interest payments on variable-rate debt that, in combination with the interest payments on the debt, convert a portion of the variable-rate debt to fixed-rate debt. At January 2, 2016, we had interest rate swaps with notional amounts totaling \$245,000. The interest rate swaps effectively convert this amount of variable-rate debt to fixed-rate debt at 2.33%, including the applicable margin of 1.63% as of January 2, 2016. The interest will revert back to variable rates based on LIBOR plus the applicable margin upon the maturity of the interest rate swaps. These interest rate swaps mature at various times between January 15, 2016 and June 5, 2017.

We use foreign currency contracts as cash flow hedges to effectively fix the exchange rates on future payments and revenue. To mitigate exposure in movements between various currencies, primarily the Philippine peso, we had outstanding foreign currency forwards with notional amounts of \$52,566 at January 2, 2016. These contracts mature at various times through September 1, 2017.

These interest rate swaps and foreign currency contracts are recorded in the consolidated condensed balance sheets at fair value and the related gains or losses are deferred in shareholders' equity as a component of Accumulated Other Comprehensive Income (Loss) (AOCI). These deferred gains and losses are reclassified into expense during the periods in which the related payments or receipts affect earnings. However, to the extent the interest rate swaps and foreign currency contracts are not perfectly effective in offsetting the change in the value of the payments and revenue being hedged, the ineffective portion of these contracts is recognized in earnings immediately. Ineffectiveness was not material in the first three months of 2016 or 2015.

## Derivatives not designated as hedging instruments

We also have foreign currency exposure on balances, primarily intercompany, that are denominated in foreign currencies and are adjusted to current values using period-end exchange rates. The resulting gains or losses are recorded in the consolidated condensed statements of earnings. To minimize foreign currency exposure, we had foreign currency contracts with notional amounts of \$108,496 at January 2, 2016. The foreign currency contracts are recorded in the consolidated condensed balance sheets at fair value and resulting gains or losses are recorded in the consolidated condensed statements of earnings. We recorded the following gains or losses on foreign currency contracts which are included in other income or expense and generally offset the gains or losses from the foreign currency adjustments on the intercompany balances that are also included in other income or expense:

7 7		Three Months Ended	
		January 2,	January 3,
		2016	2015
Net gain		\$890	\$933
Summary of derivatives			
The fair value and classification of derivatives	is summarized as follows:		
		January 2,	October 3,
		2016	2015
Derivatives designated as hedging instruments:			
Foreign currency contracts	Other current assets	\$54	\$12
Foreign currency contracts	Other assets	20	39
	Total asset derivatives	\$74	\$51
Foreign currency contracts	Other accrued liabilities	\$1,877	\$1,755
Foreign currency contracts	Other long-term liabilities	386	572
Interest rate swaps	Other accrued liabilities	215	756
Interest rate swaps	Other long-term liabilities	49	268
	Total liability derivatives	\$2,527	\$3,351
Derivatives not designated as hedging			
instruments:			
Foreign currency contracts	Other current assets	\$1,259	\$115
Foreign currency contracts	Other accrued liabilities	\$205	\$429
12			

#### Note 9 - Fair Value

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Depending on the nature of the asset or liability, various techniques and assumptions can be used to estimate fair value. The definition of the fair value hierarchy is as follows:

- Level 1 Quoted prices in active markets for identical assets and liabilities.
- Level 2 Observable inputs other than quoted prices in active markets for similar assets and liabilities.

Level 3 – Inputs for which significant valuation assumptions are unobservable in a market and therefore value is based on the best available data, some of which is internally developed and considers risk premiums that a market participant would require.

Our derivatives are valued using various pricing models or discounted cash flow analyses that incorporate observable market data, such as interest rate yield curves and currency rates, and are classified as Level 2 within the valuation hierarchy. Our Level 3 fair value liabilities represent contingent consideration recorded for acquisitions to be paid if various financial targets are met. The amounts recorded were calculated for each payment scenario in each period using an estimate of the probability of the future cash outflows. The varying contingent payments were then discounted to the present value at the weighted average cost of capital. Fair value is assessed on a quarterly basis, or whenever events or circumstances change that indicates an adjustment is required. The assessment includes an evaluation of the performance of the acquired business compared to previous expectations, changes to future projections and the probability of achieving the earn out targets.

The following table presents the fair values and classification of our financial assets and liabilities measured on a recurring basis, all of which are classified as Level 2, except for the acquisition contingent consideration which is classified as Level 3:

	Classification	January 2, 2016	October 3, 2015
Foreign currency contracts	Other current assets	\$1,313	\$127
Foreign currency contracts	Other assets	20	39
·	Total assets	\$1,333	\$166
Foreign currency contracts	Other accrued liabilities	\$2,082	\$2,184
Foreign currency contracts	Other long-term liabilities	386	572
Interest rate swaps	Other accrued liabilities	215	756
Interest rate swaps	Other long-term liabilities	49	268
Acquisition contingent consideration	Other accrued liabilities	3,000	_
	Total liabilities	\$5,732	\$3,780

The changes in financial liabilities classified as Level 3 within the fair value hierarchy are as follows:

Three Months
Ended
January 2,
2016
\$—
3,000
\$3,000

Balance at beginning of period
Additions from acquisitions
Balance at end of period

Our only financial instrument for which the carrying value differs from its fair value is long-term debt. At January 2, 2016, the fair value of long-term debt was \$1,133,450 compared to its carrying value of \$1,131,012. The fair value of long-term debt is classified as Level 2 within the fair value hierarchy and was estimated based on quoted market prices.

# Table of Contents

Note 10 - Employee Benefit Plans				
Net periodic benefit costs for U.S. defined benefit pension plans con	nsist of:		E 1 1	
		Three Months		
		January 2,	January 3,	
		2016	2015	
Service cost		\$5,909	\$5,909	
Interest cost		9,415	8,507	,
Expected return on plan assets			(11,784	)
Amortization of prior service cost (credit)		47	37 5.500	
Amortization of actuarial loss		6,542	5,589	
Pension expense for defined benefit plans		\$9,317	\$8,258	
Net periodic benefit costs for foreign defined benefit pension plans	consist of:	mi 3.6 d i	E 1 1	
		Three Months		
		January 2,	January 3,	
		2016	2015	
Service cost		\$1,313	\$1,591	
Interest cost		1,240	1,265	,
Expected return on plan assets			(1,339	)
Amortization of prior service cost (credit)		(19	(13	)
Amortization of actuarial loss		650	587	
Pension expense for defined benefit plans	. 1	\$1,955	\$2,091	
Net periodic benefit costs for the post-retirement health care benefit	t plan consists of:		F 1 1	
		Three Months		
		January 2,	January 3,	
		2016	2015	
Service cost		\$40	\$56 144	
Interest cost		117	144	`
Amortization of actuarial gain		` '	(26	)
Net periodic postretirement benefit cost		\$14	\$174	
Pension expense for the defined contribution plans consists of:		T1 M 41 1	P., 4, 4	
		Three Months		
		January 2,	January 3,	
IIC defined containation mlone		2016	2015	
U.S. defined contribution plans		\$3,441	\$3,534	
Foreign defined contribution plans		1,638	1,686	
Total pension expense for defined contribution plans	ما مسد: مناسمه ما ما ما	\$5,079	\$5,220	
Actual contributions for the three months ended January 2, 2016 and defined benefit pension plans are as follows:	d anticipated add	monai 2016 con	ributions to ou	ΙΓ
1	U.S. Plans	Foreign Plans	Total	
Actual	\$15,710	\$1,267	\$16,977	
Anticipated	52,251	5,600	57,851	
Total expected contributions	\$67,961	\$6,867	\$74,828	
•	•	•	•	
14				

### Note 11 - Restructuring

In 2016, we initiated further restructuring actions as a result of the business outlook. The restructuring actions taken have resulted in workforce reductions in Europe.

In 2015, we initiated additional restructuring plans as a result of ongoing reviews of our lines of business and operations. The restructuring actions taken resulted in workforce reductions, primarily in the U.S., Europe and Asia. In 2014, we initiated restructuring plans in response to the business outlook, which includes a change in the mix of sales and delays and cancellations of orders for certain product lines. The restructuring actions taken resulted in workforce reductions, primarily in the U.S. and Europe.

Restructuring activity for severance and other costs by segment is as follows:

	Aircraft Controls	Defense Controls	Industrial Systems	Components	Medical Devices	Total	
Balance at October 3, 2015	\$3,047	\$7,237	\$4,003	\$117	\$142	\$14,546	
Charged to expense - 2016 plan				273	_	273	
Adjustments to provision	(160	)(4	)(9	)—		(173	)
Cash payments - 2014 plan	(11	) (265	)—		_	(276	)
Cash payments - 2015 plan	(2,265	) (542	) (943	) (46	)(41	)(3,837	)
Cash payments - 2016 plan				(273	)—	(273	)
Foreign currency translation	(13	)(18	)(25	)(1	)(2	) (59	)
Balance at January 2, 2016	\$598	\$6,408	\$3,026	\$70	\$99	\$10,201	

As of January 2, 2016, the restructuring accrual consists of \$1,177 for the 2014 plan, a portion of which is classified as long-term liabilities based on payment arrangements, and \$9,024 for the 2015 plan, which will be principally paid by December 31, 2016.

### Note 12 - Income Taxes

The effective tax rates of 26.6% for the three months ended January 2, 2016 and 28.7% for the three months ended January 3, 2015 are lower than would be expected by applying the U.S. federal statutory tax rate to earnings before income taxes primarily as a result of a significant portion of our earnings that come from foreign operations with lower tax rates.

Note 13 - Shareholders' Equity

The changes in shareholders' equity for the three months ended s	Number of Shares					
	Amount	Class A Common Stock	Class B Common Stock			
COMMON STOCK Beginning of period Conversion of Class B to Class A End of Period	\$51,280 — 51,280	43,638,618 6,183 43,644,801	7,641,095 (6,183 7,634,912	)		
ADDITIONAL PAID-IN CAPITAL Beginning of period Equity-based compensation expense Issuance of treasury shares Adjustment to market - SECT, SERP and other End of period	456,512 936 (220 7,361 464,589	)				
RETAINED EARNINGS Beginning of period Net earnings attributable to common shareholders End of period	1,579,794 26,241 1,606,035					
TREASURY STOCK Beginning of period Issuance of treasury shares Purchase of treasury shares End of period	(701,771 2,450 (3,034 (702,355	82,885 ) (46,295	) (3,323,926 — ) — ) (3,323,926	)		
STOCK EMPLOYEE COMPENSATION TRUST (SECT) Beginning of period Purchase of shares Adjustment to market End of period	(44,211 (1,020 (6,049 (51,280	) ) ) ) —	(828,381 (16,561 — (844,942	)		
SUPPLEMENTAL RETIREMENT PLAN (SERP) TRUST Beginning of period Adjustment to market End of period	(5,337 (732 (6,069	) ) ) —	(100,000 — (100,000	)		
ACCUMULATED OTHER COMPREHENSIVE LOSS Beginning of period Other comprehensive income (loss) End of period TOTAL SHAREHOLDERS' EQUITY	(341,735 (17,429 (359,164 \$1,003,036	) ) ) 33,362,960	3,366,044			

17

The changes in AOCI, net of tax, by component for the three months ended January 2, 2016 are as follows:

Accumulated

		Accumulated foreign currency translation		Accumulated retirement liability		Accumulated gain (loss) on derivatives		Total	
AOCI at October 3, 2015		\$(72,788	)	\$(266,910	)	\$(2,037	)	\$(341,735	)
Other comprehensive income (loss reclassifications	) before	(23,199	)	856		(123	)	(22,466	)
Amounts reclassified from AOCI				4,476		561		5,037	
Other comprehensive income (loss	)	(23,199	)	5,332		438		(17,429	)
AOCI at January 2, 2016		\$(95,987	)	\$(261,578	)	\$(1,599	)	\$(359,164	)
The amounts reclassified from AO	CI into earnings a	are as follows:							
						Three Month	s E	Inded	
	Statement of ear	nings classific	ati	on		January 2, 2016		January 3, 2015	
Retirement liability:						2010		2010	
Prior service cost						\$28		\$293	
Actuarial losses						7,045		7,552	
Reclassification from AOCI into ea	arnings					7,073		7,845	
Tax effect	<b>6</b> -					(2,597	)	(2,271	)
Net reclassification from AOCI int	o earnings					\$4,476		\$5,574	
Derivatives:	8					, ,		, - ,	
Foreign currency contracts	Sales					\$78		<b>\$</b> —	
Foreign currency contracts	Cost of sales					476		505	
Interest rate swaps	Interest					301		405	
Reclassification from AOCI into ea	arnings					855		910	
Tax effect	_					(294	)	(344	)
Net reclassification from AOCI int	o earnings					\$561		\$566	
The amounts deferred in AOCI are	as follows:								
						Net deferral i	n A	AOCI - effectiv	ve
						portion			
						Three Month	s E	Inded	
	Statement of ear	ninge classific	ati	on		January 2,		January 3,	
	Statement of ear	illigs Classific	au	OII		2016		2015	
Foreign currency contracts	Sales					\$(234	)	<b>\$</b> —	
Foreign currency contracts	Cost of sales					(268	)	121	
Interest rate swaps	Interest					447		(629	)
Net loss						(55	)	(508	)
Tax effect						(68	)	192	
Net deferral in AOCI of derivative	S					\$(123	)	\$(316	)

Note 14 - Stock Employee Compensation Trust and Supplemental Retirement Plan Trust

The Stock Employee Compensation Trust (SECT) assists in administering and provides funding for equity-based compensation plans and benefit programs, including the Moog Inc. Retirement Savings Plan (RSP). The Supplemental Retirement Plan (SERP) Trust provides funding for benefits under the Moog Inc. SERP. Both the SECT and the SERP Trust hold shares as investments. The shares in the SECT and SERP Trust are not considered outstanding for purposes of calculating earnings per share. However, in accordance with the trust agreements governing the SECT and SERP Trust, the trustees vote all shares held by the SECT and SERP Trust on all matters submitted to shareholders.

Note 15 - Earnings per Share

Basic and diluted weighted-average shares outstanding are as follows:

	January 2, 2016	January 3, 2015
Basic weighted-average shares outstanding	36,713,949	40,594,886
Dilutive effect of equity-based awards	314,382	485,293
Diluted weighted-average shares outstanding	37,028,331	41,080,179

Three Months Ended

There were no material antidilutive equity-based awards outstanding for the three months ended January 2, 2016 and January 3, 2015.

### Note 16 - Segment Information

During 2015, we made a change to our segment reporting. Components now includes our sensor and handpieces product line, which we previously included in the Medical Devices segment. This product line consists of manufactured ultrasonic and optical sensors as well as surgical handpieces distributed to medical OEMs. Since the customer base is different from the sale of medical pumps directly to end users, the chief operating decision maker is now reviewing performance and assessing the allocation of resources of this product line as part of the Components segment. All historical amounts have been restated to conform to this new organization.

Below are sales and operating profit by segment for the three months ended January 2, 2016 and January 3, 2015 and a reconciliation of segment operating profit to earnings before income taxes. Operating profit is net sales less cost of sales and other operating expenses, excluding interest expense, equity-based compensation expense and other corporate expenses. Cost of sales and other operating expenses are directly identifiable to the respective segment or allocated on the basis of sales, number of employees or profit.

	Three Months I	Ended
	January 2,	January 3,
	2016	2015
Net sales:		
Aircraft Controls	\$254,835	\$266,368
Space and Defense Controls	82,640	99,955
Industrial Systems	125,179	133,366
Components	79,575	107,704
Medical Devices	26,228	23,130
Net sales	\$568,457	\$630,523
Operating profit:		
Aircraft Controls	\$18,131	\$24,458
Space and Defense Controls	11,816	8,726
Industrial Systems	13,633	13,219
Components	4,700	16,962
Medical Devices	3,279	2,336
Total operating profit	51,559	65,701
Deductions from operating profit:		
Interest expense	8,322	5,368
Equity-based compensation expense	936	3,398
Corporate and other expenses, net	6,646	7,497
Earnings before income taxes	\$35,655	\$49,438

### Note 17 - Commitments and Contingencies

From time to time, we are involved in legal proceedings. We are not a party to any pending legal proceedings which management believes will result in a material adverse effect on our financial condition, results of operations or cash flows.

We are engaged in administrative proceedings with governmental agencies and legal proceedings with governmental agencies and other third parties in the normal course of our business, including litigation under Superfund laws, regarding environmental matters. We believe that adequate reserves have been established for our share of the estimated cost for all currently pending environmental administrative or legal proceedings and do not expect that these environmental matters will have a material adverse effect on our financial condition, results of operations or cash flows.

In the ordinary course of business we could be subject to ongoing claims or disputes from our customers, the ultimate settlement of which could have a material adverse impact on our consolidated results of operations. While the receivables and any loss provisions recorded to date reflect management's best estimate of the projected costs to complete a given project, there is still significant effort required to complete the ultimate deliverable. Future variability in internal cost and as well as future profitability is dependent upon a number of factors including deliveries, performance and government budgetary pressures. The inability to achieve a satisfactory contractual solution, further unplanned delays, additional developmental cost growth or variations in any of the estimates used in the existing contract analysis could lead to further loss provisions. Additional losses could have a material adverse impact on our financial condition, results of operations or cash flows in the period in which the loss may be recognized.

We are contingently liable for \$16,027 of standby letters of credit issued by a bank to third parties on our behalf at January 2, 2016.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following should be read in conjunction with Management's Discussion and Analysis of Financial Condition and Results of Operations contained in the Company's Annual Report filed on Form 10-K for the fiscal year ended October 3, 2015. All references to years in this Management's Discussion and Analysis of Financial Condition and Results of Operations are to fiscal years and amounts may differ from reported values due to rounding. OVERVIEW

We are a worldwide designer, manufacturer and systems integrator of high performance precision motion and fluid controls and control systems for a broad range of applications in aerospace and defense and industrial markets. Within the aerospace and defense market, our products and systems include:

Defense market - primary and secondary flight controls for military aircraft, stabilization and automatic ammunition loading controls for armored combat vehicles, tactical and strategic missile steering controls and gun aiming controls. Commercial aircraft market - primary and secondary flight controls for commercial aircraft.

Commercial space market - space satellite positioning controls and thrust vector controls for space launch vehicles.

In the industrial market, our products are used in a wide range of applications including:

Industrial automation market - injection molding, metal forming, heavy industry, material and automotive testing, pilot training simulators and surveillance systems.

Energy market - oil and gas exploration, wind energy and power generation.

Medical market - motors used in sleep apnea devices, enteral clinical nutrition and infusion therapy pumps, ultrasonic sensors and surgical handpieces and CT scanners.

We operate under five segments, Aircraft Controls, Space and Defense Controls, Industrial Systems, Components and Medical Devices. Our principal manufacturing facilities are located in the United States, United Kingdom, Philippines, Germany, Italy, Netherlands, China, Costa Rica, Japan, Luxembourg, India, Canada and Ireland. We have long-term contracts with some of our customers. These contracts are predominantly within Aircraft Controls and Space and Defense Controls and represent 33%, 34% and 33% of our sales in 2015, 2014 and 2013, respectively. We recognize revenue on these contracts using the percentage of completion, cost-to-cost method of accounting as work progresses toward completion. The remainder of our sales are recognized when the risks and rewards of ownership and title to the product are transferred to the customer, principally as units are delivered or as service obligations are satisfied. This method of revenue recognition is predominantly used within the Industrial Systems, Components and Medical Devices segments, as well as with aftermarket activity.

We concentrate on providing our customers with products designed and manufactured to the highest quality standards. Our products are applied in demanding applications, "When Performance Really Matters®." We believe we have achieved a leadership position in the high performance, precision controls market, by capitalizing on our strengths, which include:

- superior technical competence in delivering mission-critical solutions,
- an innovative customer-intimacy approach,
- a diverse base of customers and end markets served by a broad product portfolio,
- well-established international presence serving customers worldwide, and
- a proven ability to successfully undertake investments designed to enhance our control systems product franchise and drive continued growth.

These strengths afford us the ability to innovate our current solutions into new, complimentary technologies, providing us the opportunity to expand our product scope supply from one market to another and from component to systems supplier. In addition, we will continue to strive for achieving substantial content positions on the platforms on which we currently participate, seeking to be the dominant supplier in the current niche markets we serve. We also look for innovation in all aspects of our business, employing new technologies to improve productivity and to develop

innovative business models.

Our financial objectives include increasing our revenue base and improving our long term profitability and cash flow from operations while continuously focusing on internal cost improvement initiatives. In doing so, we expect to maintain a balanced, diversified portfolio in terms of markets served, product applications, customer base and geographic presence. Our fundamental strategies to achieve our objectives include:

maintaining our technological excellence by building upon our systems integration capabilities while solving our customers' most demanding technical problems in applications "When Performance Really Matter®,"

utilizing our global capabilities and strong engineering heritage to innovate,

growing our profitable aftermarket business,

maximizing customer value by implementing lean enterprise principles, and

investing in talent development to accelerate our leadership capability and employee performance.

We focus on improving shareholder value through strategic revenue growth, both acquired and organic, through improving operating efficiencies and manufacturing initiatives and through utilizing low cost manufacturing facilities without compromising quality. Additionally, we take a balanced approach to capital deployment, which may include strategic acquisitions or further share buyback activity in order to maximize shareholder returns over the long-term. We face numerous challenges to improving shareholder value. These include, but are not limited to, adjusting to dynamic global economic conditions that are influenced by governmental, industrial and commercial factors, pricing pressures from customers, strong competition, foreign currency fluctuations and increases in employee benefit costs. Based on periodic strategy reviews, including the financial outlook of our business, we may also engage in restructuring activities, including reducing overhead, consolidating facilities, exiting some product lines and divesting operations.

## Acquisition and Divestiture

All of our acquisitions are accounted for under the purchase method and, accordingly, the operating results for the acquired companies are included in the consolidated statements of earnings from the respective dates of acquisition. Under purchase accounting, we record assets and liabilities at fair value on the consolidated balance sheet. The purchase price described for each acquisition below is net of any cash acquired and includes debt issued or assumed.

In 2016, we acquired a 70% ownership in Linear Mold and Engineering, a Livonia, Michigan-based company providing engineering, manufacturing and production consulting services to customers across a wide range of industries, including aerospace, defense, energy and industrial. We acquired Linear Mold and Engineering for \$26 million, which includes contingent consideration with an initial fair value of \$3 million. The acquisition also includes a redeemable noncontrolling interest in the remaining 30%, which is exercisable beginning three years from the date of acquisition. This acquisition is included in of our Aircraft Controls segment.

In 2015, we sold the Rochester, New York and Erie, Pennsylvania life sciences operations of our Medical Devices segment for \$3 million.

#### CRITICAL ACCOUNTING POLICIES

On a regular basis, we evaluate the critical accounting policies used to prepare our consolidated financial statements, including, but not limited to, revenue recognition on long-term contracts, contract loss reserves, reserves for inventory valuation, reviews for impairment of goodwill, purchase price allocations for business combinations, pension assumptions and deferred tax asset valuation allowances.

There have been no material changes in critical accounting policies in the current year from those disclosed in our 2015 Annual Report on Form 10-K. However, we have expanded our disclosure for reviews for impairment of

goodwill. The disclosure below includes key assumptions and circumstances that, if changed, could negatively impact our assessment of goodwill in reporting units for which the fair value is not significantly in excess of carrying value.

### Reviews for Impairment of Goodwill

We performed an interim test on goodwill for impairment for our Medical Devices reporting unit in the fourth quarter of 2015. This reporting unit had \$62 million of goodwill at October 3, 2015. The fair value of the Medical Devices reporting unit exceeded its carrying amount by 18%. Had we used a discount rate that was 100 basis points higher or a terminal growth rate that was 100 basis points lower than those we assumed, the fair value of this reporting unit would have exceeded its carrying amount by 4% and 10%, respectively.

The primary factor causing the fair value of this reporting unit to not be substantially greater than the carrying value is that the Medical Devices segment was created through a series of acquisitions between 2006 and 2009. The creation of this reporting unit resulted in recording substantial goodwill, which increased the carrying value. The key assumptions that drive the estimated fair value are the projected revenue and operating margins, which are used to project future cash flows. Our expectation for this reporting unit is for revenue growth over the five year projection period to be driven by the overall market growth of the home healthcare segment of the infusion therapy market and by capturing market share due to new product offerings. Additionally, our expectation is that operating margins improve throughout the five year projection period, driven by improved sales, as well as continued cost containment activities. If cash flows generated by our Medical Devices reporting unit were to decline in the future, or if there were adverse revisions to key assumptions, we may be required to record impairment charges. There are specific circumstances that would pose risk to the fair value of this reporting unit. Lower than projected growth rates of the home healthcare segment of the infusion therapy market, changes in provider capital purchase cycles, changes in healthcare legislation, changes in private insurance plans, as well as changes in treatment therapies may negatively affect the fair value of this reporting unit. Also, our projected market share capture rates may be lower due to delayed or unsuccessful new product offerings, which would negatively affect the fair value of this reporting unit. In addition, the fair value of this reporting unit may be negatively impacted based on the results of our strategic review and the courses of action that we may decide to pursue.

### RECENT ACCOUNTING PRONOUNCEMENTS

In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)," which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. This ASU requires revenue recognition to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires additional disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and assets recognized from costs incurred to obtain or fulfill a contract. This ASU can be applied using one of two prescribed retrospective methods, and no early adoption is permitted. The provisions of this ASU are effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years, pursuant to the issuance of ASU No. 2015-14, "Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date," in August 2015. This amendment is applicable to us beginning in the first quarter of 2019. We are currently evaluating the adoption of this standard on our financial statements.

In August 2014, the FASB issued ASU No. 2014-13, "Consolidation (Topic 810): Measuring the Financial Assets and Financial Liabilities of a Consolidated Collateralized Financing Entity." This ASU allows a reporting entity to elect to measure the financial assets and the financial liabilities of a consolidated collateralized financing entity using either the measurement alternative included in the ASU or Topic 820. The provisions of this ASU are effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. Early adoption is permitted as of the beginning of an annual period. This amendment is applicable to us beginning in the first quarter of 2017. The adoption of this standard is not expected to have a material impact on our financial statements.

In August 2014, the FASB issued ASU No. 2014-15, "Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosures of Uncertainties about an Entity's Ability to Continue as a Going Concern." This ASU requires management to evaluate whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued or are available to be issued. This ASU also requires management to disclose certain information depending on the results of the going concern evaluation. The provisions of this ASU are effective for fiscal years ending after December 15, 2016 and for

interim periods within those fiscal years thereafter. Early adoption is permitted. This amendment is applicable to us beginning in the first quarter of 2017. The adoption of this standard is not expected to have a material impact on our financial statements.

In January 2015, the FASB issued ASU No. 2015-01, "Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items." This ASU eliminates from GAAP the concept of extraordinary items. The ASU retains and expands the existing presentation and disclosure guidance for items that are unusual in nature or occur infrequently to also include items that are both unusual in nature and infrequently occurring. The provisions of this ASU are effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. Early adoption is permitted, provided that presentation applied to the beginning of the fiscal year of adoption. This amendment is applicable to us beginning in the first quarter of 2017. The adoption of this standard is not expected to have a material impact on our financial statements.

In April 2015, the FASB issued ASU No. 2015-03, "Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs." This ASU requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The provisions of this ASU are effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. Early adoption is permitted, and retrospective application is required. This amendment is applicable to us beginning in the first quarter of 2017. The adoption of this standard is not expected to have a material impact on our financial statements.

In May 2015, the FASB issued ASU No. 2015-07, "Fair Value Measurement (Topic 820): Disclosures for Investments in Certain Entities that Calculate Net Asset Value per Share (or Its Equivalent)." This ASU removes the requirement to make certain disclosures as well as categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The provisions of this ASU are effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. Early adoption is permitted, and retroactive application is required. This amendment is applicable to us beginning in the first quarter of 2017. Other than requiring a change to our disclosures, the adoption of this standard is not expected to have a material impact on our financial statements.

In July 2015, the FASB issued ASU No. 2015-11, "Inventory (Topic 330): Simplifying the Measurement of Inventory." This ASU requires inventory to be measured at the lower of cost or net realizable value. The provisions of this ASU are effective for fiscal years beginning after December 15, 2016 and interim periods within those fiscal years. Early adoption is permitted, and the amendment is required to be applied prospectively. This amendment is applicable to us beginning in the first quarter of 2018. The adoption of this standard is not expected to have a material impact on our financial statements.

In August 2015, the FASB issued ASU No. 2015-15, "Interest - Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements." This ASU provides additional guidance on ASU No. 2015-03, specific to debt issuance costs arising from line-of-credit arrangements. This ASU provides an option to either apply the provisions of ASU No. 2015-03 to line-of-credit arrangements or to defer and instead present debt issuance costs as an asset and subsequently amortize the deferred debt issuance costs ratably over the term of the line-of-credit arrangement. The additional guidance does not alter any other effective date provisions set forth in ASU No. 2015-03. The adoption of this standard is not expected to have a material impact on our financial statements.

In September 2015, the FASB issued ASU No. 2015-16, "Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments." This ASU eliminates the requirement to retrospectively account for changes to provisional amounts initially recorded in a business acquisition opening balance sheet. The provisions of this ASU are effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. Early adoption is permitted as of the effective date for financial statements that have not yet been made available for issuance. This amendment is applicable to us beginning in the first quarter of 2017. The adoption of this standard is not expected to have a material impact on our financial statements.

In November 2015, the FASB issued ASU No. 2015-17, "Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes." This ASU amends existing guidance to require presentation of deferred tax assets and liabilities as noncurrent within the balance sheet. The provisions of the ASU are effective for fiscal years beginning after

December 15, 2016 and interim periods within those fiscal years. Early adoption is permitted, and may be applied either prospectively or retrospectively. This amendment is applicable to us beginning in the first quarter of 2018. We are currently evaluating the adoption of this standard on our financial statements.

In January 2016, the FASB issued ASU No. 2016-01, "Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities." This ASU requires most equity investments be measured at fair value, with subsequent changes in fair value recognized in net income. The amendment also impacts the measurement of financial liabilities under the fair value option as well as certain presentation and disclosure requirements for financial instruments. The provisions of this ASU are effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years. Early adoption is permitted for some, but not all, provisions. The amendment requires certain provisions to be applied prospectively and others to be applied by means of a cumulative-effect adjustment. This amendment is applicable to us beginning in the first quarter of 2018. We are currently evaluating the adoption of this standard on our financial statements.

### CONSOLIDATED RESULTS OF OPERATIONS AND OUTLOOK

	Three Months Ended						
(dollars and shares in millions, except per share data)	January 2, 2	2016 January 3, 2	2015 <sup>\$</sup> Varianc	e % Var	riance		
Net sales	\$568	\$631	\$(62	)(10	%)		
Gross margin	28.4	% 29.2	%				
Research and development expenses	\$35	\$31	\$3	11	%		
Selling, general and administrative expenses as a percentage of sales	of 14.6	% 15.5	%				
Interest expense	\$8	\$5	\$3	55	%		
Effective tax rate	26.6	% 28.7	%				
Net earnings attributable to common shareholders	\$26	\$35	\$(9	)(26	%)		
Average common shares outstanding	37	41	(4	)(10	%)		
Diluted earnings per share attributable to common shareholders	\$0.71	\$0.86	\$(0.15	)(17	%)		

Net sales decreased in the first quarter of 2016 compared to the first quarter of 2015 as all of our segments' sales declined with the exception of Medical Devices. Weaker foreign currencies, in particular the Euro relative to the U.S. dollar, contributed 26% of the sales decline in 2016.

Gross margin declined in the first quarter of 2016 compared to the first quarter of 2015 due to an adverse sales mix. We were negatively impacted by lower energy and industrial market sales in both Industrial Systems and in Components. The decline was partly offset by the benefits realized from the 2015 restructuring activities and the absence of prior year inventory obsolescence charges.

Research and development expenses increased in the first quarter of 2016 compared to the same period of 2015. Within Aircraft Controls, research and development expenses increased \$5 million as activity on Embraer E-Jets accelerated.

Selling, general and administrative expenses as a percentage of sales decreased in the first quarter of 2016 compared to the first quarter of 2015. Most of the decline is due to an on-going focus on expense reduction.

In the first quarter of 2016 compared to the first quarter of 2015, interest expense increased \$2 million due to higher cost debt following the issuance of our \$300 million senior notes. Additionally, interest expense increased \$1 million due to higher levels of debt attributable to funding our share repurchase program.

The effective tax rate in the first quarter of 2016 was lower than the effective tax rate in first quarter of 2015, as we benefited from the enactment of legislation reinstating the research and development tax credit in the U.S. Average common shares outstanding decreased in the first quarter of 2016 compared to the same period of 2015 due to our share buyback program. Since the Board of Directors amended the program in January 2014, we have repurchased nine million shares, and have four million additional shares available under this program. Other comprehensive loss decreased in the first quarter of 2016 compared to the first quarter of 2015. Foreign currency translation adjustments decreased \$20 million, primarily attributable to the Euro and the British Pound. 2016 Outlook – We expect sales in 2016 to decrease 2% to \$2.47 billion. We expect sales declines in Components and Industrial Systems as they are negatively impacted by global macro-economic conditions, particularly in our energy market and in our industrial market. Partly offsetting the declines is growth in Aircraft Controls as the Airbus A350 program continues to ramp up. We expect operating margin to increase slightly to 9.8%. The benefits of our 2015 cost containment strategies will drive margin expansion; however, the improvement will be offset by unfavorable sales mix in Aircraft Controls and Components. We expect net earnings will decrease 6% to \$124 million. Average diluted shares outstanding will decrease 6% to 37 million due to shares already repurchased under our current share buyback program. We expect diluted earnings per share will range between \$3.20 and \$3.50, with the midpoint of \$3.35; which would be unchanged from 2015.

### SEGMENT RESULTS OF OPERATIONS AND OUTLOOK

During 2015, we made a change to our segment reporting. Components now includes our sensor and handpieces product line, which we previously included in the Medical Devices segment. This product line consists of manufactured ultrasonic and optical sensors as well as surgical handpieces distributed to medical OEMs. Since the customer base is different from the sale of medical pumps directly to end users, the chief operating decision maker is now reviewing performance and assessing the allocation of resources of this product line as part of the Components segment. Sales of sensors and handpieces were \$25 million in 2015. All amounts have been restated to present sensors and handpieces within Components.

Operating profit, as presented below, is net sales less cost of sales and other operating expenses, excluding interest expense, equity-based compensation expense and other corporate expenses. Cost of sales and other operating expenses are directly identifiable to the respective segment or allocated on the basis of sales, number of employees or profit. Operating profit is reconciled to earnings before income taxes in Note 16 of the Notes to Consolidated Condensed Financial Statements included in this report.

Thurs Months Ended

Aircraft Controls

	Three Months Ended						
(dollars in millions)	January 2, 2	5	% nce Variance				
Net sales - military aircraft	\$120	\$126	\$(6	) (5	%)		
Net sales - commercial aircraft	135	140	(6	)(4	%)		
	\$255	\$266	\$(12	)(4	%)		
Operating profit	\$18	\$24	\$(6	)(26	%)		
Operating margin	7.1	%9.2	%				
Backlog	\$643	\$711	\$(68	)(10	%)		

Aircraft Controls' net sales decreased in the first quarter of 2016 compared to the first quarter of 2015 in both our commercial and military markets.

Commercial OEM sales declined \$4 million in the first quarter of 2016 compared to the same period of 2015 due to lower volumes across multiple programs, including business jets and legacy Boeing programs. Military OEM sales declined \$4 million due, in part, to lower volume on the V-22 program. Military and commercial aftermarket sales each declined \$2 million in the first quarter of 2016.

Operating margin for the first quarter of 2016 declined compared to the first quarter of 2015. Research and development expenses associated with the ramp up of the Embraer E-Jets program increased \$5 million compared to the same quarter of 2015. Additionally, we had an adverse sales mix due to lower amounts of military and commercial aftermarket sales and due to lower amounts of military OEM sales. However, the operating profit included \$1 million of restructuring benefits realized from restructuring activities in the fourth quarter of 2015. These year-to-date savings are approximately 20% of our total expected annual benefits and are in line with our expectations.

The decrease of twelve-month backlog for Aircraft Controls at January 2, 2016 compared to January 3, 2015 is primarily due to work completed on military programs as well as the timing of certain commercial orders. 2016 Outlook for Aircraft Controls – We expect sales in Aircraft Controls to increase 2% to \$1.11 billion in 2016. Commercial OEM aircraft sales are expected to increase 15%, due primarily to the continued ramp up of the Airbus A350 program. We expect that commercial aftermarket sales will continue to decline due to the lower levels of Boeing 787 initial provisioning sales. We expect military sales will decline 2% in 2016, as lower V-22 and military aftermarket sales offset higher F-35 production sales. We expect our operating margin will decrease slightly to 9.0% in 2016 from 9.2% in 2015. We expect operating margin pressures to be a result of an unfavorable sales mix associated with lower amounts of military and commercial aftermarket sales. Additionally, our research and development costs will remain elevated due to the continued spend on the A350 and the Embraer E-2 programs. However, we expect the benefits of our restructuring actions in 2015 will offset some of the margin pressures.

## Space and Defense Controls

	Three Months Ended				
(dollars in millions)	January 2	, 2016 January 3,	2015 \$ Variance	% ce Varia	nce
Net sales	\$83	\$100	\$(17	)(17	%)
Operating profit	\$12	\$9	\$3	35	%
Operating margin	14.3	%8.7	%		
Backlog	\$235	\$276	\$(41	)(15	%)

Th.... M. ... L. .. E. . 1. . 1

Space and Defense Controls' net sales decreased in the first quarter of 2016 compared to the first quarter of 2015 as sales declined in both our space and defense markets.

Sales in our space market decreased \$13 million in the first quarter of 2016 compared to the same period of 2015, due primarily to satellite and launch vehicle programs winding down. Within defense, sales declined \$5 million as the prior year's high amount of security sales did not repeat.

Operating margin increased in the first quarter of 2016 compared to the same period of 2015. We benefited from an improved sales mix, in part due to completing various satellite programs, as well as from cost containment activities. Additionally, we benefited from the absence of a \$2 million inventory obsolescence charge in our security market. The operating profit also included \$1 million of restructuring benefits from restructuring activities in 2015. These year-to-date savings are approximately 30% of our total expected annual benefits and are in line with our expectations. The lower level of twelve-month backlog for Space and Defense Controls at January 2, 2016 compared to January 3, 2015 is due to the completion of satellite production contracts as well as lower levels of follow-on orders. 2016 Outlook for Space and Defense Controls – We expect sales in Space and Defense Controls to decrease 2% to \$375 million in 2016. We expect sales increases in our defense market to be driven by increased production volumes for missile systems. Offsetting this growth is an expected decline in our space market as production programs continue to wind down. We expect our operating margin will increase to 12.0% in 2016 from 8.7% in 2015 as the 2015 accounting correction does not repeat and as we benefit from our 2015 restructuring actions.

## **Industrial Systems**

•	Three Months Ended					
(dollars in millions)	January 2,	2016 January 3,	2015 \$Variance	% ce Varia	nce	
Net sales	\$125	\$133	\$(8	)(6	%)	
Operating profit	\$14	\$13	\$	3	%	
Operating margin	10.9	%9.9	%			
Backlog	\$166	\$176	\$(11	)(6	%)	

Industrial Systems' net sales decreased across our industrial automation and energy markets in the first quarter of 2016 compared to the first quarter of 2015. Weaker foreign currencies, in particular the Euro relative to the U.S. dollar, resulted in \$11 million of the sales decline.

Sales in our industrial automation market decreased \$7 million in the first quarter of 2016 compared to the first quarter of 2015. Unfavorable foreign currency translation contributed approximately 80% of the decline. The remaining decline is attributable to the unfavorable global macro-economic conditions in Europe and lower aftermarket sales. Sales in our energy market decreased \$6 million, with approximately half of the decline due to unfavorable foreign currency translation. Additionally, sales of our non-renewable energy products decreased \$4 million due to the unfavorable macro-economic conditions related to the significant decline in the price of crude oil. Partly offsetting the decline was a \$5 million sales increase within our simulation and test market, due to higher sales volumes in both material testing and simulation programs.

Operating margin increased in the first quarter of 2016 compared to the first quarter of 2015. General cost containment activities helped improve the margin. Operating profit also included \$1 million of restructuring benefits from restructuring activities in 2015. These year-to-date savings are approximately 20% of our total expected annual benefits and are in line with our expectations. Partly offsetting the improvements was an unfavorable sales mix in our energy and industrial automation markets.

The lower level of twelve-month backlog in Industrial Systems at January 2, 2016 compared to January 3, 2015 is due the impact of foreign currency translation.

2016 Outlook for Industrial Systems – We expect sales in Industrial Systems to decrease 5% to \$495 million in 2016, as the evolving global economic conditions continue to negatively impact our energy and industrial automation markets. We expect our operating margin will increase to 9.2% in 2016 from 8.6% in 2015, as we benefit from both our restructuring actions in the fourth quarter of 2015 and our cost containment actions.

### Components

	Three Months Ended				
(dollars in millions)	January 2	, 2016 January 3,	2015 \$Variance	% ce Varia	nce
Net sales	\$80	\$108	\$(28	)(26	%)
Operating profit	\$5	\$17	\$(12	)(72	%)
Operating margin	5.9	% 15.7	%		
Backlog	\$170	\$183	\$(13	)(7	%)

Components' net sales decreased across all of our markets in the first quarter of 2016 compared to the first quarter of 2015.

Within our non-aerospace and defense market, sales decreased \$21 million in the first quarter of 2016 compared to the first quarter of 2015. Sales in our marine market declined \$10 million, due to the macro-economic conditions centered around the significant decline in the price of crude oil and the resulting lower demand for our marine products. Additionally, sales declined \$6 million in our medical market due to a lower price point for a key customer's next generation sleep apnea product that we will continue to support. Sales in our industrial market also declined \$4 million due to unfavorable macro-economic industrial conditions, including the stronger U.S. dollar and the economic slowdown in China. Within our aerospace and defense market, sales decreased \$7 million, due primarily to lower amounts of military aftermarket sales.

Operating margin declined in first quarter of 2016 compared to the first quarter of 2015. The decrease is in part due to lower demand for our marine energy products resulting from the significant decline in the price of crude oil. Additionally, lower sales in our medical market and unfavorable timing of sales in our military market negatively impacted operating margin.

The twelve-month backlog at January 2, 2016 declined compared to the level at January 3, 2015 due to reduced orders for our marine energy products, as well as timing of defense orders.

2016 Outlook for Components – We expect sales to decrease 17% to \$365 million in 2016 due to continued declines in our energy, our industrial and our medical markets. Partially offsetting these declines is expected growth in our space and defense market, driven by improved foreign military vehicle program sales. We expect our operating margin will decrease to 10.0% in 2016 from 13.4% in 2015. We will continue to be negatively impacted by macro-economic conditions reducing demand for products in our energy and industrial markets.

#### Medical Devices

	Three Months Ended				
(dollars in millions)	January 2	, 2016 January 3	3, 2015 \$Variance	% Varia	nce
Net sales	\$26	\$23	\$3	13	%
Operating profit	\$3	\$2	\$1	40	%
Operating margin	12.5	% 10.1	%		
Backlog	\$2	\$7	\$(6	) (77	%)

Medical Devices' net sales increased in the first quarter of 2016 compared to the first quarter of 2015, with sales growth in both our IV and enteral products offsetting declines in our other product category.

Sales for IV products increased \$2 million in the first quarter of 2016 compared to the first quarter of 2015. Approximately half of the growth in IV pump sales was due to the continued replacement of competitors' older products in the U.S. home healthcare market. Sales for enteral products increased \$2 million due to higher sales volume to a distributor partner. Partly offsetting the sales growth was a decline of \$2 million in the first quarter of 2016 due to lost sales associated with the sale of two small operations in 2015.

Operating margin in the first quarter of 2016 increased compared to the first quarter of 2015 due to higher sales volumes, primarily for our IV products, a more favorable sales mix across both of our IV and enteral products and lower operational costs.

Twelve-month backlog for Medical Devices at January 2, 2016 declined compared to the level at January 3, 2015. Last year's backlog was unusually high due to the unfavorable timing of orders for our enteral and IV products. 2016 Outlook for Medical Devices – We expect sales to increase slightly to \$102 million in 2016. We expect that sales will increase due to improved enteral product sales, as well as higher IV sets sales due to a higher installed base. However, this growth will be offset by a reduction related to the operations we sold in 2015. We expect our operating margin will increase to 11.4% in 2016 from 8.7% in 2015 as we continue to benefit from an improved cost structure and incremental margin contribution from higher sales volumes.

### FINANCIAL CONDITION AND LIQUIDITY

	Three Months Ended							
(dollars in millions)	January 2, 2016		January 3, 2015		\$ Variance	)	% Variance	ee
Net cash provided (used) by:								
Operating activities	<b>\$</b> —		\$78		\$(79	)	(101	%)
Investing activities	(22	)	(20	)	(2	)	11	%
Financing activities	44		(40	)	84		(211	%)

Our available borrowing capacity and our cash flow from operations provide us with the financial resources needed to run our operations, reinvest in our business and make strategic acquisitions.

At January 2, 2016, our cash balance was \$323 million, which is primarily held outside of the U.S. Cash flow from our U.S. operations, together with borrowings on our credit facility, fund on-going activities, debt service requirements and future growth investments. We reinvest the cash generated from foreign operations locally and such international balances are not available to pay down debt in the U.S. unless we decide to repatriate such amounts. If we determined repatriation of foreign funds was necessary, we would then be required to pay U.S. income taxes on those funds.

# Operating activities

Net cash provided by operating activities decreased in the first quarter of 2016 compared to the same period of 2015. Cash provided by accounts receivable decreased \$58 million, as the favorable timing in the fourth quarter of 2015 reversed in the first quarter of 2016 across all of our segments. Additionally, cash used by accounts payable decreased \$16 million due to timing across all of our segments except Medical Devices.

## Investing activities

Net cash used by investing activities in the first quarter of 2016 included \$12 million for capital expenditures and \$11 million as partial payment for the Linear acquisition. Net cash used by investing activities in the first quarter of 2015 included \$20 million for capital expenditures.

We expect our 2016 capital expenditures to be approximately \$80 million, as we support the increased production of commercial aircraft.

## Financing activities

Cash provided by financing activities in the first quarter of 2016 includes net proceeds of our credit facility. Cash used by financing activities in the first quarter of 2015 includes the net proceeds of issuing our \$300 million aggregate principal 5.25% senior notes, which were used to repay our revolving credit facility borrowings. Additionally, financing activities in the first quarter of 2015 includes \$106 million to fund our stock repurchase program.

### Off Balance Sheet Arrangements

We do not have any material off balance sheet arrangements that have or are reasonably likely to have a material future effect on our results of operations or financial condition.

## Contractual Obligations and Commercial Commitments

Our contractual obligations and commercial commitments have not changed materially from the disclosures in our 2015 Annual Report on Form 10-K.

#### CAPITAL STRUCTURE AND RESOURCES

We maintain bank credit facilities to fund our short and long-term capital requirements, including for acquisitions. From time to time, we also sell debt and equity securities to fund acquisitions or take advantage of favorable market conditions

On November 21, 2014, we completed the sale of \$300 million aggregate principal amount of 5.25% senior notes due December 1, 2022 at par with interest paid semiannually on June 1 and December 1 of each year. The senior notes are unsecured obligations, guaranteed on a senior unsecured basis by certain subsidiaries and contain normal incurrence-based covenants and limitations such as the ability to incur additional indebtedness, pay dividends, make other restricted payments and investments, create liens and certain corporate acts such as mergers and consolidations. The aggregate net proceeds of \$294 million were used to repay indebtedness under our U.S. bank credit facility, thereby increasing the unused portion of our U.S. revolving credit facility.

Our U.S. revolving credit facility has a capacity of \$1,100 million and matures on May 22, 2019. It also provides an expansion option, which permits us to request an increase of up to \$200 million to the credit facility upon satisfaction of certain conditions. The U.S. revolving credit facility had an outstanding balance of \$730 million at January 2, 2016. Interest on the outstanding credit facility borrowings is based on LIBOR plus the applicable margin, which was 1.63% at January 2, 2016 and will increase to 1.88% during the second quarter of 2016. The credit facility is secured by substantially all of our U.S. assets.

The U.S. revolving credit facility contains various covenants. The covenant for minimum interest coverage ratio, defined as the ratio of EBITDA to interest expense for the most recent four quarters, is 3.0. The covenant for the maximum leverage ratio, defined as the ratio of net debt, including letters of credit, to EBITDA for the most recent four quarters, is 3.5. The covenant for maximum capital expenditures is \$185 million for 2016 and increases by \$10 million each year thereafter. We are in compliance with all covenants. EBITDA is defined in the loan agreement as (i) the sum of net income, interest expense, income taxes, depreciation expense, amortization expense, other non-cash items reducing consolidated net income and non-cash equity-based compensation expenses minus (ii) other non-cash items increasing consolidated net income.

We are generally not required to obtain the consent of lenders of the U.S. revolving credit facility before raising significant additional debt financing; however, certain limitations and conditions may apply that would require consent to be obtained. In recent years, we have demonstrated our ability to secure consents to access debt markets. We have also been successful in accessing equity markets from time to time. We believe that we will be able to obtain additional debt or equity financing as needed.

At January 2, 2016, we had \$366 million of unused capacity, including \$354 million from the U.S. revolving credit facility after considering standby letters of credit. However, our leverage ratio covenant limits our borrowing capacity to \$268 million as of January 2, 2016.

We have a trade receivables securitization facility (the "Securitization Program"), which terminates on February 10, 2017. Under the Securitization Program, we sell certain trade receivables and related rights to an affiliate, which in turn sells an undivided variable percentage ownership interest in the trade receivables to a financial institution, while maintaining a subordinated interest in a portion of the pool of trade receivables. The Securitization Program effectively increases our borrowing capacity by up to \$100 million and lowers our cost to borrow funds as compared to the U.S. revolving credit facility. We had an outstanding balance of \$100 million at January 2, 2016. The Securitization Program has a minimum borrowing requirement, which was \$80 million at January 2, 2016. Interest on the secured borrowings under the Securitization Program was 1.18% at January 2, 2016 and is based on 30-day LIBOR plus an applicable margin.

Net debt to capitalization was 45% at January 2, 2016 and 44% at October 3, 2015.

We believe that our cash on hand, cash flows from operations and available borrowings under short and long-term arrangements will continue to be sufficient to meet our operating needs.

The Board of Directors authorized a share repurchase program beginning in January 2014 that includes both Class A and Class B common shares, and allows us to buy up to an aggregate 13.0 million common shares. Under this program, we have purchased approximately 8.8 million shares for \$611 million as of January 2, 2016.

## ECONOMIC CONDITIONS AND MARKET TRENDS

We operate within the aerospace and defense and industrial markets. Our aerospace and defense markets are affected by market conditions and program funding levels, while our industrial markets are influenced by general capital investment trends and economic conditions. A common factor throughout our markets is the continuing demand for technologically advanced products.

# Aerospace and Defense

Approximately 64% of our 2015 sales were generated in aerospace and defense markets. Within aerospace and defense, we serve three end markets: defense, commercial aircraft and space.

The defense market is dependent on military spending for development and production programs. Aircraft production programs are typically long-term in nature, offering predictability as to capacity needs and future revenues. We maintain positions on numerous high priority programs, including the Lockheed Martin F-35 Joint Strike Fighter, FA-18E/F Super Hornet and V-22 Osprey. The large installed base of our products leads to attractive aftermarket sales and service opportunities. The tactical and strategic missile, missile defense and defense controls markets are dependent on many of the same market conditions as military aircraft, including overall military spending and program funding levels. Our security and surveillance product line is dependent on government funding at federal and local levels, as well as private sector demand.

Reductions in the U.S. Department of Defense's mandatory and discretionary budgeted spending, which became effective on March 1, 2013, resulting from the Budget Control Act of 2011, will have ongoing ramifications for the domestic aerospace and defense market for the near future. The automatic spending limitations (which is generally referred to as sequestration) of approximately \$500 billion through the Federal Government's 2021 fiscal year will present challenges over the next decade, as uncertainty remains with respect to the levels of defense spending. We believe that our military sales remain likely to be most affected due to lower defense spending. Currently, we expect approximately \$670 million of U.S. defense sales in 2016.

The commercial aircraft market is dependent on a number of factors, including global demand for air travel, which generally follows underlying economic growth. As such, the commercial aircraft market has historically exhibited cyclical swings which tend to track the overall economy. In recent years, the development of new, more fuel-efficient commercial air transports has helped drive increased demand in the commercial aircraft market, as airlines replace older, less fuel-efficient aircraft with newer models in an effort to reduce operating costs. The aftermarket is driven by usage of the existing aircraft fleet and the age of the installed fleet, and is impacted by fleet re-sizing programs for passenger and cargo aircraft. Changes in aircraft utilization rates affect the need for maintenance and spare parts and impact aftermarket sales. Boeing and Airbus have historically adjusted production in line with air traffic volume. Demand for our commercial aircraft products is in large part dependent on new aircraft production, which is increasing as Boeing and Airbus work to fulfill large backlogs of unfilled orders.

The commercial space market is comprised of large satellite customers, traditionally communications companies. Trends for this market, as well as for commercial launch vehicles, follow demand for increased capacity. This in turn, tends to track with underlying demand for increased consumption of telecommunication services, satellite replacement and global navigation needs. The space market is also partially dependent on the governmental-authorized levels of funding for satellite communications, as well as investment for commercial and exploration activities.

Approximately 36% of our 2015 sales were generated in industrial markets. Within industrial, we serve three end markets: industrial automation, energy and medical.

The industrial automation market we serve is influenced by several factors including capital investment, product innovation, economic growth, cost-reduction efforts and technology upgrades. We experience challenges from the need to react to the demands of our customers, who are in large part sensitive to international and domestic economic conditions.

The energy market we serve is affected by changing oil and natural gas prices, global urbanization, the resulting change in supply and demand for global energy and the political climate and corresponding public support for investments in renewable energy generation capacity. Historically, drivers for global growth include investments in power generation infrastructure, including renewable energy, and exploration in search of new oil and gas resources. However, the recent significant decline in the price of crude oil has reduced investment in exploration activities. This reduced investment has directly affected our energy business in Components and in Industrial Systems. Currently, we expect approximately \$40 million of oil exploration-related sales in 2016, down from approximately \$100 million in 2014.

The medical market we serve is influenced by economic conditions, regulatory environments, hospital and outpatient clinic spending on equipment, population demographics, medical advances, patient demands and the need for precision control components and systems. Advances in medical technology and medical treatments have had the effect of extending the average life spans, in turn resulting in greater need for medical services. These same technology and treatment advances also drive increased demand from the general population as a means to improve quality of life. Access to medical insurance, whether through government funded health care plans or private insurance, also affects the demand for medical services.

## Foreign Currencies

We are affected by the movement of foreign currencies compared to the U.S. dollar, particularly in Industrial Systems. About one-quarter of our 2015 sales were denominated in foreign currencies. During the first three months of 2016, average foreign currency rates generally weakened against the U.S. dollar compared to 2015. The translation of the results of our foreign subsidiaries into U.S. dollars decreased sales by \$16 million compared to the same period one year ago.

### **Cautionary Statement**

Information included or incorporated by reference in this report that does not consist of historical facts, including statements accompanied by or containing words such as "may," "will," "should," "believes," "expects," "expected," "intends," "projects," "approximate," "estimates," "predicts," "potential," "outlook," "forecast," "anticipates," "presume" and "assume," forward-looking statements. Such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are not guarantees of future performance and are subject to several factors, risks and uncertainties, the impact or occurrence of which could cause actual results to differ materially from the expected results described in the forward-looking statements. These important factors, risks and uncertainties include:

the markets we serve are cyclical and sensitive to domestic and foreign economic conditions and events, which may cause our operating results to fluctuate;

• we operate in highly competitive markets with competitors who may have greater resources than we possess;

we depend heavily on government contracts that may not be fully funded or may be terminated, and the failure to receive funding or the termination of one or more of these contracts could reduce our sales and increase our costs; we make estimates in accounting for long-term contracts, and changes in these estimates may have significant impacts on our earnings;

we enter into fixed-price contracts, which could subject us to losses if we have cost overruns;

we may not realize the full amounts reflected in our backlog as revenue, which could adversely affect our future revenue and growth prospects;

if our subcontractors or suppliers fail to perform their contractual obligations, our prime contract performance and our ability to obtain future business could be materially and adversely impacted;

contracting on government programs is subject to significant regulation, including rules related to bidding, billing and accounting kickbacks and false claims, and any non-compliance could subject us to fines and penalties or possible debarment;

the loss of The Boeing Company as a customer or a significant reduction in sales to The Boeing Company could adversely impact our operating results;

our new product research and development efforts may not be successful which could reduce our sales and earnings; our inability to adequately enforce and protect our intellectual property or defend against assertions of infringement could prevent or restrict our ability to compete;

our business operations may be adversely affected by information systems interruptions, intrusions or new software implementations;

our indebtedness and restrictive covenants under our credit facilities could limit our operational and financial flexibility;

significant changes in discount rates, rates of return on pension assets, mortality tables and other factors could adversely affect our earnings and equity and increase our pension funding requirements;

a write-off of all or part of our goodwill or other intangible assets could adversely affect our operating results and net worth;

our sales and earnings may be affected if we cannot identify, acquire or integrate strategic acquisitions, or if we engage in divesting activities;

our operations in foreign countries expose us to political and currency risks and adverse changes in local legal and regulatory environments;

unforeseen exposure to additional income tax liabilities may affect our operating results;

government regulations could limit our ability to sell our products outside the United States and otherwise adversely affect our business;

governmental regulations and customer demands related to conflict minerals may adversely impact our operating results;

# Edgar Filing: MOOG INC. - Form 10-Q

the failure or misuse of our products may damage our reputation, necessitate a product recall or result in claims against us that exceed our insurance coverage, thereby requiring us to pay significant damages;

future terror attacks, war, natural disasters or other catastrophic events beyond our control could negatively impact our business;

our operations are subject to environmental laws, and complying with those laws may cause us to incur significant costs; and

we are involved in various legal proceedings, the outcome of which may be unfavorable to us.

These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. Given these factors, risks and uncertainties, investors should not place undue reliance on forward-looking statements as predictive of future results. We disclaim any obligation to update the forward-looking statements made in this report.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Refer to the Company's Annual Report on Form 10-K for the year ended October 3, 2015 for a complete discussion of our market risk. There have been no material changes in the current year regarding this market risk information. Item 4. Controls and Procedures.

Disclosure Controls and Procedures. We carried out an evaluation, under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Exchange Act Rules 13a-15(e) and 15d-15(e). Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that these

- disclosure controls and procedures are effective as of the end of the period covered by this report, to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.
- Changes in Internal Control over Financial Reporting. There have been no changes in our internal control over (b) financial reporting during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## PART II OTHER INFORMATION

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

(c) The following table summarizes our purchases of our common stock for the quarter ended January 2, 2016.

				(d) Maximum
			(c) Total number	Number (or
	(a) Total		of Shares	Approx.
	Number of	(b) Average	Purchased as	Dollar Value) of
Period	Shares	Price Paid	Part of Publicly	Shares that May
	Purchased	Per Share	Announced	Yet Be
	(1)(2)		Plans	Purchased
			or Programs (3)	Under Plans or
				Programs (3)
October 4, 2015 - October 31, 2015	8,007	\$59.60	_	4,202,555
November 1, 2015 - November 30, 2015	21,571	63.18		4,202,555
December 1, 2015 - January 2, 2016	33,278	66.53	_	4,202,555
Total	62,856	\$64.50	_	4,202,555

Reflects purchases by the SECT of shares of Class B common stock from the Moog Inc. RSP as follows: 8,007 (1) shares at \$59.60 per share during October; 6,172 shares at \$63.79 per share during November; and 1,382 shares at \$63.13 per share during December. Purchases by the SECT from members of the Moog family included: 1,000 shares of Class B common stock at \$61.76 per share on November 2, 2015.

In connection with the exercise of equity-based compensation awards, we accept delivery of shares to pay for the exercise price and withhold shares for tax withholding obligations. In November, we accepted delivery of 14,399 shares at \$63.02 per share and in December, 31,896 shares at \$66.68 per share, in connection with the exercise of equity based awards.

In August 2014, the Board of Directors authorized a share repurchase program. The program permitted the purchase of up to 5,000,000 shares of Class A or Class B common stock in open market or privately negotiated

(3) transactions at the discretion of management. In August 2015, the Board of Directors authorized an additional repurchase of up to 4,000,000 shares of Class A or Class B common stock at management's discretion, under identical terms and conditions.

## Edgar Filing: MOOG INC. - Form 10-Q

#### **Table of Contents**

#### Item 6. Exhibits.

(a)	Exhibits

- Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- Certification of Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 101 Interactive Date files (submitted electronically herewith)
- (101.INS) XBRL Instance Document
- (101.SCH) XBRL Taxonomy Extension Schema Document
- (101.CAL) XBRL Taxonomy Extension Calculation Linkbase Document
- (101.DEF) XBRL Taxonomy Extension Definition Linkbase Document
- (101.LAB) XBRL Taxonomy Extension Label Linkbase Document
- (101.PRE) XBRL Taxonomy Extension Presentation Linkbase Document

In accordance with Rule 406T of Regulation S-T, the XBRL related information in Exhibit 101 to this Quarterly Report on Form 10-Q shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section and shall not be part of any registration or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Moog Inc.

(Registrant)

Date: February 1, 2016 By /s/ John R. Scannell

John R. Scannell

Chairman Chief Executive Officer (Principal Executive Officer)

Date: February 1, 2016 By /s/ Donald R. Fishback

Donald R. Fishback Vice President

Chief Financial Officer (Principal Financial Officer)

Date: February 1, 2016 By /s/ Jennifer Walter

Jennifer Walter

Controller (Principal Accounting

Officer)